Skip to content

#强生

Today 0 items
Oct 13Tue
  1. biospace.com52

    J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent

    Johnson & Johnson posted overall Q3 revenue of $25.4 billion, with innovative medicines up about 8% to $16.76 billion while medtech grew only 2.5% to $8.64 billion. Tremfya sales rose 68% to just under $2.4 billion, Darzalex grew 15% to $4.24 billion, and Icotyde, approved in March for plaque psoriasis, has reached about 20,000 patients against a $10 billion sales expectation. Charges of $5.52 billion for the talc settlement and a $339 million impairment cut EPS to about 9 cents, and CFO Joseph Wolk pledged internal investment to fix medtech.

    Why it matters: J&J's results open pharma earnings season and detail medtech weakness, drug launch progress and talc settlement charges.

Oct 9Fri
  1. biopharmadive.com61

    TRex Bio prices $117M IPO to support immune drug work

    TRex Bio priced a $117 million IPO, selling 8,333,334 shares at $14 each, and begins trading Friday on Nasdaq under "TRXB." The company is developing Treg-activating drugs for immunological conditions, including TRB-061, in a Phase 1 trial with topline data expected in 2027, and TRB-071 for inflammatory bowel disease, which could enter testing next year. Eli Lilly, TRex's largest equity holder at about 24% pre-IPO, and Johnson & Johnson have licensed or optioned treatments discovered by TRex, which has raised $220 million in venture financing to date.

    Why it matters: IPO shows continued investor appetite for immune-focused biotechs, with six of 23 drug developers going public in 2026 working on immune diseases.

Oct 8Thu
  1. biospace.com40

    Q3 layoffs down YOY, with 90% fewer biopharma employees affected

    BioSpace tallies show biopharma layoffs fell sharply year over year in Q3, with a 56% drop in companies making or projecting cuts and a 90% plunge in affected employees; the 27 companies and 2,568 people affected are the lowest quarterly figures since tracking began in 2024. Eight Big Pharma companies accounted for cuts of 1,845 employees in the quarter, including Bristol Myers Squibb letting go of 265 people in Princeton, New Jersey, GSK closing a German vaccine site with about 650 job losses, and Novartis, whose 2026 disclosures total at least 922 people. Novo CEO Mike Maziar Doustdar said overall headcount has dropped by 13,000 over the past year, including 9,000 layoffs under a restructuring announced in September 2025 targeting around $1.25 billion in annualized savings.

Sep 30Wed
  1. biospace.com40

    GSK laying off 1.2K+ in Belgium

    GSK is laying off more than 1,200 employees in Belgium, part of a wave of biopharma job cuts in 2026 tracked by BioSpace. Other reductions include Novo Nordisk's workforce shrinking by about 13,000 people over the past year to 67,000 as it shifts money into R&D, Takeda cutting over 4,700 jobs, and Bristol Myers Squibb terminating 265 employees at its Princeton, New Jersey site between Dec. 17, 2026 and May 21, 2027. Layoffs tied to M&A include BioNTech letting go of around 800 people at CureVac.

Aug 14Fri
  1. FiercePharma40

    Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve

    Legend Biotech posted its first profitable quarter, with $63 million in adjusted net income for the three months ended June, as interim CEO Alan Bash discussed expanding Carvykti amid competition from Johnson & Johnson's bispecifics. Taiho and Cullinan Therapeutics' EGFR inhibitor zipalertinib plus chemotherapy succeeded in a phase 3 trial in first-line EGFR exon 20-mutated non-small cell lung cancer, with FDA approval plans ahead. A federal judge granted WuXi AppTec a preliminary injunction blocking the Defense Department's 1260H Chinese military company designation, and China approved Akeso's ivonescimab with chemotherapy for first-line squamous NSCLC.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org